Pharnext SA   Report issue

For profit Phase 2 Phase 3
Founded: Paris France (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2010
NCT01401257
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Pharnext SA

Active Ingredients

Drugs in Phase 3 Trials (4)

baclofen (lioresal) (1 trial)

naltrexone (revia) (1 trial)

pxt3003 (3 trials)

sorbitol (1 trial)

Drugs in Phase 2 Trials (1)

pxt00864 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Charcot-Marie-Tooth Disease (Phase 3)

Genetic Diseases, Inborn (Phase 2)

Hereditary Sensory and Motor Neuropathy (Phase 3)

Nerve Compression Syndromes (Phase 3)

Tooth Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5